Cumulative, additive benefits of memantine-donepezil combination over component monotherapies in moderate to severe Alzheimer's dementia: A pooled area under the curve analysis

Alzheimer's Research and Therapy

Volumn 7, Issue 1, 2015, Pages

  Atri, Alireza ^a,b   Hendrix, Suzanne B ^c   Pejović, Vojislav ^d   Hofbauer, Robert K ^e   Edwards, John ^e   Molinuevo, José Luis ^f,g   Graham, Stephen M ^e  

^a CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c Pentara Corporation   (United States)

^d Prescott Medical Communications Group   (United States)

^e FOREST RESEARCH INSTITUTE   (United States)

^f HOSPITAL CLÍNIC   (Spain)

^g BarcelonaBeta Brain Research Center BBRC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

DONEPEZIL; DONEPEZIL PLUS MEMANTINE; MEMANTINE; PLACEBO;

ADD ON THERAPY; AGED; ALZHEIMER DISEASE; AREA UNDER THE CURVE; ARTICLE; BEHAVIOR ASSESSMENT; CLINICAL EFFECTIVENESS; COGNITION ASSESSMENT; CONTROLLED STUDY; DISEASE CLASSIFICATION; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; FEMALE; FUNCTIONAL ASSESSMENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MINI MENTAL STATE EXAMINATION; MONOTHERAPY; MULTICENTER STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 84929441442     PISSN: None     EISSN: 17589193     Source Type: Journal    
DOI: 10.1186/s13195-015-0109-2     Document Type: Article

References (32)

1. Parsons CG, Stoffler A, Danysz W. Memantine: a NMDA receptor antagonist that improves memory by restoration of homeostasis in the glutamatergic system-too little activation is bad, too much is even worse. Neuropharmacology. 2007;53:699-723.
2. Birks J. Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006;1:CD005593.
3. McShane R, Areosa Sastre A, Minakaran N. Memantine for dementia. Cochrane Database Syst Rev. 2006;2:CD003154.
4. Parsons CG, Danysz W, Dekundy A, Pulte I. Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease. Neurotox Res. 2013;24:358-69.
5. Grossberg GT, Manes F, Allegri RF, Gutiérrez-Robledo LM, Gloger S, Xie L, et al. The safety, tolerability, and efficacy of once-daily memantine (28 mg): a multinational, randomized, double-blind, placebo-controlled trial in patients with moderate-to-severe Alzheimer's disease taking cholinesterase inhibitors. CNS Drugs. 2013;27:469-78.
6. Reisberg B, Doody R, Stoffler A, Schmitt F, Ferris S, Möbius HJ, et al. Memantine in moderate-to-severe Alzheimer's disease. N Engl J Med. 2003;348:1333-41.
7. Tariot PN, Farlow MR, Grossberg GT, Graham SM, McDonald S, Gergel I, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. JAMA. 2004;291:317-24.
8. van Dyck CH, Tariot PN, Meyers B, Malca Resnick E. Memantine MEM-MD-01 Study Group. A 24-week randomized, controlled trial of memantine in patients with moderate-to-severe Alzheimer disease. Alzheimer Dis Assoc Disord. 2007;21:136-43.
9. Atri A, Molinuevo JL, Lemming O, Wirth Y, Pulte I, Wilkinson D. Memantine in patients with Alzheimer's disease receiving donepezil: new analyses of efficacy and safety for combination therapy. Alzheimers Res Ther. 2013;5:6.
10. Atri A, Shaughnessy LW, Locascio JJ, Growdon JH. Long-term course and effectiveness of combination therapy in Alzheimer disease. Alzheimer Dis Assoc Disord. 2008;22:209-21.
11. Lopez OL, Becker JT, Wahed AS, Saxton J, Sweet RA, Wolk DA, et al. Longterm effects of the concomitant use of memantine with cholinesterase inhibition in Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009;80:600-7.
12. Rountree SD, Chan W, Pavlik VN, Darby EJ, Siddiqui S, Doody RS. Persistent treatment with cholinesterase inhibitors and/or memantine slows clinical progression of Alzheimer disease. Alzheimers Res Ther. 2009;1:7.
13. Arrighi HM, Gelinas I, McLaughlin TP, Buchanan J, Gauthier S. Longitudinal changes in functional disability in Alzheimer's disease patients. Int Psychogeriatr. 2013;25:929-37.
14. Atri A. Alzheimer's disease & Alzheimer's dementia. In: Dickerson BC, Atri A, editors. Dementia comprehensive principles and practice. New York, NY: Oxford University Press; 2014. p. 360-41.
15. Honig LS, Mayeux R. Natural history of Alzheimer's disease. Aging. 2001;13:171-82.
16. Atri A. Considering time and space: area under the curve analysis to improve detection of treatment effects in Alzheimer's disease. CTAD 2011 Symposium 3. J Nutrition Health Aging. 2011;15:S2-S3.
17. Carusone SC, Goldsmith CH, Smieja M, Loeb M. Summary measures were a useful alternative for analyzing therapeutic clinical trial data. J Clin Epidemiol. 2006;59:387-92.
18. Locascio JJ, Atri A. An overview of longitudinal data analysis methods for neurological research. Dement Geriatr Cogn Dis Extra. 2011;1:330-57.
19. Matthews JN, Altman DG, Campbell MJ, Royston P. Analysis of serial measurements in medical research. BMJ. 1990;300:230-5.
20. Schiff M. A rationale for the use of summary measurements for the assessment of the effects of rheumatoid arthritis therapies. Clin Ther. 2003;25:993-1001.
21. Cummings JL. Challenges to demonstrating disease-modifying effects in Alzheimer's disease clinical trials. Alzheimers Dement. 2006;2:263-71.
22. Panisset M, Roudier M, Saxton J, Boller F. Severe impairment battery. A neuropsychological test for severely demented patients. Arch Neurol. 1994;51:41-5.
23. Schmitt FA, Ashford W, Ernesto C, Saxton J, Schneider LS, Clark CM, et al. The severe impairment battery: concurrent validity and the assessment of longitudinal change in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S51-6.
24. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11 Suppl 2:S33-9.
25. Galasko D, Schmitt F, Thomas R, Jin S, Bennett D, Alzheimer's Disease Cooperative Study. Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease. J Int Neuropsychol Soc. 2005;11:446-53.
26. Cummings JL. The Neuropsychiatric Inventory: assessing psychopathology in dementia patients. Neurology. 1997;48:S10-6.
27. Schneider LS, Olin JT, Doody RS, Clark CM, Morris JC, Reisberg B, et al. Validity and reliability of the Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord. 1997;11:S22-2.
28. Atri A, Rountree SD, Lopez OL, Doody RS. Validity, significance, strengths, limitations, and evidentiary value of real-world clinical data for combination therapy in Alzheimer's disease: comparison of efficacy and effectiveness studies. Neurodegener Dis. 2012;10:170-4.
29. Rountree SD, Atri A, Lopez OL, Doody RS, et al. Effectiveness of antidementia drugs in delaying Alzheimer's disease progression: validity, significance, strengths, limitations, and evidentiary value of real-world clinical data for combination therapy in Alzheimer's disease: comparison of efficacy and effectiveness studies. Alzheimers Dement. 2013;9:338-45.
30. Spooner DM, Pachana NA. Ecological validity in neuropsychological assessment: a case for greater consideration in research with neurologically intact populations. Arch Clin Neuropsychol. 2006;21:327-37.
31. Kozauer N, Katz R. Regulation of drugs for early Alzheimer's disease: regulatory innovation and drug development for early-stage Alzheimer's disease. N Engl J Med. 2013;369:288.
32. Schneider LS. Rethinking the Food and Drug Administration's 2013 guidance on developing drugs for early-stage Alzheimer's disease. Alzheimers Dement. 2014;10:247-50.